Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT05267626 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

159

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Metastatic Cancer
Cutaneous Melanoma
Non-Small Cell Lung Cancer

Interventions

DRUG: AU-007
DRUG: Aldesleukin
DRUG: Avelumab
DRUG: Nivolumab

Sponsor

Aulos Bioscience, Inc.